366 related articles for article (PubMed ID: 29566415)
1. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
Camm AJ
Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Kruger PC; Eikelboom JW; Yusuf S
Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
[No Abstract] [Full Text] [Related]
3. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
Bauersachs R; Zannad F
Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413
[TBL] [Abstract][Full Text] [Related]
4. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
Khorana AA; Weitz JI
Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
[TBL] [Abstract][Full Text] [Related]
5. Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Gibson CM; Hankey GJ; Nafee T; Welsh RC
Thromb Haemost; 2018 May; 118(S 01):S34-S44. PubMed ID: 29566416
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban in peripheral artery disease: The new kid on the block?
Hussain MA; Verma S; Al-Omran M
J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
[No Abstract] [Full Text] [Related]
8. A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
Filippatos G; Farmakis D
Cardiovasc Res; 2019 Nov; 115(13):e140-e142. PubMed ID: 31638158
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
[TBL] [Abstract][Full Text] [Related]
10. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Fox KAA; Eikelboom JW; Anand SS; Bhatt DL; Bosch J; Connolly SJ; Harrington RA; Steg PG; Yusuf S
Eur Heart J; 2019 May; 40(18):1466-1471. PubMed ID: 29945212
[No Abstract] [Full Text] [Related]
11. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban.
Tardy-Poncet B; Piot M; Montmartin A; Burdier A; Chalayer E; Tardy B
Thromb Haemost; 2015 Aug; 114(3):652-4. PubMed ID: 26062524
[No Abstract] [Full Text] [Related]
12. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
Ambler GK; Nordanstig J; Behrendt CA; Twine CP
Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837
[No Abstract] [Full Text] [Related]
13. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Dangas GD; Tijssen JGP; Wöhrle J; Søndergaard L; Gilard M; Möllmann H; Makkar RR; Herrmann HC; Giustino G; Baldus S; De Backer O; Guimarães AHC; Gullestad L; Kini A; von Lewinski D; Mack M; Moreno R; Schäfer U; Seeger J; Tchétché D; Thomitzek K; Valgimigli M; Vranckx P; Welsh RC; Wildgoose P; Volkl AA; Zazula A; van Amsterdam RGM; Mehran R; Windecker S;
N Engl J Med; 2020 Jan; 382(2):120-129. PubMed ID: 31733180
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism.
Seoane L; Cortés M; Aris Cancela ME; Furmento J; Baranchuk A; Conde D
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):501-514. PubMed ID: 29862875
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and drug safety of rivaroxaban in the prevention and treatment of senile thromboembolic diseases.
Hongwei L; Li R; Daoli G
Pak J Pharm Sci; 2020 Jan; 33(1(Special)):409-415. PubMed ID: 32173635
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
17. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
18. Successful COMPASS, Disappointing COMMANDER HF, What Have We Learned From These Two Trials?
He Y; Hu X; Zhou S
J Cardiovasc Pharmacol; 2019 Oct; 74(4):306-307. PubMed ID: 31356557
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
[TBL] [Abstract][Full Text] [Related]
20. Intravenous thrombolysis for acute ischemic stroke in a patient receiving rivaroxaban.
Landais A; Ginoux C
J Stroke Cerebrovasc Dis; 2015 Mar; 24(3):e73-4. PubMed ID: 25561312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
